BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 11, 2026
Breaking News: Read BioWorld's AACR 2026 coverageBreaking News: Best of BioWorld: Q1
Home » Topics » BioWorld, Regulatory

BioWorld, Regulatory
BioWorld, Regulatory RSS Feed RSS

Regulatory front for Feb. 4, 2020

Feb. 4, 2020
The latest global regulatory news, changes and updates affecting biopharma, including: Sanofi, Glaxosmithkline, Novartis.
Read More

Influenza A protection and a peanut allergy treatment receive FDA approvals

Feb. 3, 2020
By Lee Landenberger
The FDA has issued two new approvals, one for a cell-based pandemic influenza A (H5N1) vaccine and the other is the first approval for treating peanut allergy.
Read More

Australia’s Mesoblast submits final module of rolling BLA submission for pediatric GVHD stem cell therapy

Feb. 3, 2020
By Tamra Sami
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. has filed the final module of its rolling BLA submission for its allogeneic mesenchymal precursor cell therapy, remestemcel-L, after it showed strong survival rates in children with acute steroid-refractory graft-vs.-host disease (aGVHD).
Read More

Japan’s drug repricing plan to hit some top sellers

Feb. 3, 2020
By Jihyun Kim
HONG KONG – Aiming to increase the financial stability of the national health care insurance system, Japan has announced a list of 17 drugs for which prices will be reduced.
Read More

Regulatory front for Feb. 3, 2020

Feb. 3, 2020
The latest global regulatory news, changes and updates affecting biopharma, including: Vanda Pharmaceuticals.
Read More
Brexit hourglass illustration

Brexit day arrives; industry continues to face lack of clarity as transition period begins

Jan. 31, 2020
By Nuala Moran
LONDON – Brexit finally becomes a reality at midnight central European time on Jan. 31, but for the life sciences industry uncertainty continues, as the U.K. enters an 11-month transition phase during which the terms of its future relationship with the EU must be negotiated.
Read More

EU panel CHMPions varied batch of prospective new therapies

Jan. 31, 2020
By Randy Osborne
The EMA’s Committee for Medicinal Products for Human Use (CHMP) looked with favor on a bucketload of would-be drugs, issuing positive opinions for the European Commission to consider across a range of indications.
Read More
Time perception clocks

With rapid transmission of 2019-nCoV, how fast is fast enough for communication?

Jan. 31, 2020
By Anette Breindl and Elise Mak
BEIJING – The current speed of new developments in the 2019-nCov outbreak is illustrated by a Jan. 28, 2020, press conference in Munich, where Andreas Zapf, head of the infection task force in the Bavarian ministry for health and food safety, briefed reporters on the first confirmed German case.
Read More

Regulatory front for Jan. 30, 2020

Jan. 30, 2020
The latest global regulatory news, changes and updates affecting biopharma.
Read More

Regulatory front for Jan. 29, 2020

Jan. 29, 2020
The latest global regulatory news, changes and updates affecting biopharma.
Read More
Previous 1 2 … 436 437 438 439 440 441 442 443 444 … 455 456 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 11, 2026.
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Infensa Bioscience identifies new ASIC blockers

    BioWorld Science
    Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • Neurology illustration

    Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst

    BioWorld
    Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing